Acute Blood Flow Restriction Walking on Immune Cell Phenotype and Function
Impact of Acute Blood Flow Restriction Walking on Immune Cell Phenotype and Function in Adults withT2D
To conduct a randomized control trial to determine the impact of acute blood flow restriction treadmill walking on immune cell counts, function, and phenotype in adults living with type 2 diabetes.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Participants will be randomized to a regular treadmill walking condition or treadmill walking with blood flow restriction (BFR) condition. In both groups participants will complete 32 minutes of treadmill walking at a speed and grade that elicit 40-50% heart rate reserve. In the BFR group the cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 minute every 10 minutes based on safety recommendations. The percentage of LOP will 60%. Blood samples will be obtained pre-exercise (PRE), during the final 2 minutes of the final occlusion cycle (OCC), and 3 minutes into the recovery period post-exercise (POST) to measure outcomes.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jonathan P Little, PhD
- Número de telefone: 250-807-9876
- E-mail: jonathan.little@ubc.ca
Locais de estudo
-
-
British Columbia
-
Kelowna, British Columbia, Canadá, V1V 1V7
- Recrutamento
- University of British Columbia Okanagan
-
Contato:
- Jonathan P Little, PhD
- Número de telefone: 250-807-9876
- E-mail: jonathan.little@ubc.ca
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged 19-64 years
- Diagnosed with type 2 diabetes with current HbA1c 5.7-9.0%
- Completing <150 minutes of moderate-vigorous physical activity per week.
Exclusion Criteria:
- Chronic musculoskeletal condition or recent (within 2 years) cardiovascular event preventing participation in exercise.
- Unstable type 2 diabetes medication of the last 3 months
- Absolute contraindications to BFR (i.e., peripheral vascular disease)
- A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions
- A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis)
- Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely
- Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Treadmill walking with blood flow restriction
Treadmill walking with blood flow restriction. |
Participants will complete 32 minutes of treadmill walking at a speed and grade that elicit 40-50% heart rate reserve. The cuffs will be inflated based on each participants individualized limb occlusion pressure (LOP). The cuffs will remain inflated for the entire session but will deflate for 1 minute every 10 minutes based on safety recommendations. The percentage of LOP will 60%. |
|
Comparador Ativo: Treadmill Walking
Treadmill walking. |
Participants will complete 32 minutes of treadmill walking at a speed and grade that elicit 40-50% heart rate reserve. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in white blood cell count before, during, and after exercise.
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The white blood cell count will be measured using a hematology analyzer before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in monocyte count before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The monocyte count will be measured using a hematology analyzer before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in neutrophil count before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The neutrophil count will be measured using a hematology analyzer before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in eosinophil count before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The eosinophil count will be measured using a hematology analyzer before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in CD66b+ expression before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The CD66b+ expression will be measured using flow cytometry before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in CD11b+ expression before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The CD11b+ expression will be measured using flow cytometer before, during, and after exercise |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in CD63+ expression before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The CD63+ expression will be measured using flow cytometry before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in % of classical monocytes before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The % of classical monocytes will be measured using flow cytometry before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in % of intermediate monocytes before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The % of intermediate monocytes will be measured using flow cytometry before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in % of non-classical monocytes before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The % of non-classical monocytes will be measured using flow cytometry before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in TLR-4 expression on classical monocytes before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The TLR-4 expression on classical monocytes will be measured using flow cytometry before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in TLR-4 expression on intermediate monocytes before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The TLR-4 expression on intermediate monocytes will be measured using flow cytometry before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in TLR-4 expression on non-classical monocytes before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The TLR-4 expression on non-classical monocytes will be measured using flow cytometry before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in plasma IL-6 before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The plasma IL-6 concentration will be measured using a multiplex assay before, during, and after exercise |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in plasma IL-10 before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The plasma IL-10 concentration will be measured using a multiplex assay before, during, and after exercise. |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in plasma TNF-α before, during, and after exercise
Prazo: Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
The plasma TNF-α concentration will be measured using a multiplex assay before, during, and after exercise |
Pre-exercise, during 32 minute of exercise, immediately post-exercise
|
|
Change in 4-h LPS-induced TNF-α before and after exercise
Prazo: Pre-exercise, immediately post-exercise
|
The LPS-induced TNF-α concentration will be measured from whole-blood culture supernatant using an ELISA before and after exercise. |
Pre-exercise, immediately post-exercise
|
|
Change in 4-h LPS+IL10-induced TNF-α before and after exercise
Prazo: Pre-exercise, immediately post-exercise
|
The LPS+IL10-induced TNF-α concentration will be measured from whole-blood culture supernatant using an ELISA before and after exercise. |
Pre-exercise, immediately post-exercise
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- H25-02870 acute
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .